Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features-Reference-Cited by-同舟云学术

Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features

Published:2019-04-30 Issue:6 Volume:71 Page:1011-1021
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Moneta Gian Marco¹,Pires Marafon Denise¹,Marasco Emiliano¹^ORCID,Rosina Silvia²,Verardo Margherita¹,Fiorillo Chiara²,Minetti Carlo³,Bracci‐Laudiero Luisa⁴,Ravelli Angelo³,De Benedetti Fabrizio¹,Nicolai Rebecca¹

Affiliation:

1. Ospedale Pediatrico Bambino GesùIRCCS Rome Italy

2. University of Genoa Genoa Italy

3. University of Genoa and Istituto Giannina GasliniIRCCS Genoa Italy

4. Ospedale Pediatrico Bambino GesùIRCCS, Consiglio Nazionale delle Ricerche Rome Italy

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40800

Reference33 articles.

1. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood

2. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment

3. Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients

4. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

5. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating cell-free DNA promotes inflammation in dermatomyositis patients with anti-NXP2 antibodies via the cGAS/STING pathway;Rheumatology;2024-08-07

2. Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice;Best Practice & Research Clinical Rheumatology;2024-08

3. Autologous CD19‐Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis;Arthritis & Rheumatology;2024-07-31

4. Over Activation of IL-6/STAT3 Signaling Pathway in Juvenile Dermatomyositis;Rheumatology and Therapy;2024-07-29

5. JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study;Journal of Autoimmunity;2024-07